# Use of anakinra in cryopyrin-associated periodic syndromes: case report and review of literature

## TL;DR

A 66-year-old man with a rare inflammatory condition was successfully treated with anakinra, a drug that blocks a key inflammatory protein.

## Contribution

This case report highlights the successful use of anakinra in treating a rare autoinflammatory syndrome caused by a specific mutation.

## Key findings

- Anakinra effectively resolved symptoms in a patient with cryopyrin-associated periodic syndrome.
- The treatment was well-tolerated and led to significant clinical improvement.
- The case supports the use of interleukin-1 inhibitors for this rare condition.

## Abstract

Cryopyrin-associated periodic syndrome is a rare autoinflammatory syndrome caused by a dysregulation of cytokine signaling pathways, particularly of the interleukin-1β production. Symptoms typical appear early in life and include recurrent fever, arthralgia, and cutaneous rash, often accompanied by systemic manifestations and progressive end-organ damage resulting from chronic inflammation. Interleukin- targeted therapy constitutes the basis for treatment, and can lead to complete resolution of symptoms. We report a case of a 66-year-old man with cryopyrin-associated periodic syndrome related to V198M mutation, successfully treated with anakinra, an interleukin- 1 inhibitor frequently used in rheumatoid arthritis.